IN
INSP.K
—
NYSE
Health Care Equipment & Supplies
Insp.K
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
5,6 %
ROE
18,6 %
Net margin
15,9 %
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$51,07
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Inspire Medical Systems Inc (INSP.K) operates in the Health Care Equipment & Supplies industry, generating revenue through the sale of medical devices and related services.
Business. Inspire Medical Systems Inc (INSP.K) operates in the Health Care Equipment & Supplies industry, generating revenue through the sale of medical devices and related services.
Classification85 %
SectorHealth Care
Industry groupHealth Care Equipment & Supplies
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
Wellington Management Company, LLP
largest disclosed fund holder
Profitability→
18,6 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to INSP.K. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Inspire Medical Systems Inc (INSP.K) operates in the Health Care Equipment & Supplies industry, generating revenue through the sale of medical devices and related services.
Classification85 %
SectorHealth Care
Industry groupHealth Care Equipment & Supplies
AI synthesis
GENERATED(a) Capital structure and liquidity are characterized by a conservative balance sheet with zero debt-to-equity ratio and $104.8 million in cash and equivalents against $126.2 million in total liabilities. The company maintains a low liquidity risk profile, supported by $117.0 million in operating cash flow, which exceeds its $38.5 million capital expenditure requirement, indicating strong internal cash generation capabilities.
(b) Profitability metrics demonstrate strong returns, with a return on equity of 18.62% and a return on assets of 16.03%. The company reported net income of $145.4 million on revenue of $912.0 million, resulting in a net margin of approximately 15.9%, while operating income stood at $51.0 million, suggesting significant non-operating income or tax benefits contributing to the bottom line.
Key takeaways
- The company maintains a debt-free balance sheet with a $104.8 million cash position, resulting in a zero debt-to-equity ratio.
- Strong profitability is evidenced by an 18.62% return on equity and 16.03% return on assets.
- Operating cash flow of $117.0 million significantly exceeds capital expenditures of $38.5 million, ensuring robust liquidity.
- Net income of $145.4 million exceeds operating income of $51.0 million, indicating material non-operating contributions.
- Low risk profile is confirmed by low liquidity and dilution risk assessments with no immediate flags.
- Lack of historical data and segment breakdowns limits the depth of growth and concentration analysis.
Bull / Bear case
analysis pipeline— missing data
In focus — financials by report
Valuation
Market price
$51,07
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
$781.2M
Net cashⓘ
$104.8M
Current ratioⓘ
—
Debt / equityⓘ
—
ROAⓘ
16.0%
ROEⓘ
18.6%
Cash conversionⓘ
80.0%
CapEx / revenueⓘ
4.2%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution18 analysts
Strong buy1
Buy3
Hold12
Sell2
Strong sell0
12-month price target$61,40 · Median $55,00
Low $39,00High $180,00
Operating income · consensus24,8M USD
EPS surprise
+400,0 %
reported vs consensus · beat
Revenue surprise
+8,1 %
reported vs consensus · beat
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$39,00
Mean$61,40
Median$55,00
High$180,00
Spot$51,07
+20.2 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin5,6 %Above median
Net Margin16,0 %Above P75
ROE18,6 %Above P75
Capex / Rev4,2 %Above P75
D/E0,00Above median
Cash Conv0,80Below median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
— missing data
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Cash Conversion Ratiooperating_cash_flow / net_income
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Capex To Revenuecapital_expenditure / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
Source documents
- Inspire Medical Systems, Inc. Market data — financials · 2026-07-30
- reconciler_enqueue (reconciler) on INSP.K · 2026-07-30
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,02 %$131M
- Investment Managers · as of 2024-12-310,01 %$28M
- Investment Managers · as of 2026-03-310,01 %$16M
- Investment Managers · as of 2026-03-310,01 %$33M
- Investment Managers · as of 2024-06-300,01 %$249M
- Investment Managers · as of 2026-03-310,00 %$75M
- Investment Managers · as of 2026-03-310,00 %$34M
- Investment Managers · as of 2025-12-310,00 %$272M
- Investment Managers · as of 2026-03-310,00 %$7M
- Investment Managers · as of 2026-03-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$12M
- Investment Managers · as of 2026-03-310,00 %$3M
- Institutional Investor · as of 2026-03-310,00 %$7M
- Investment Managers · as of 2026-03-310,00 %$49M
- Investment Managers · as of 2026-03-310,00 %$26M
- Investment Managers · as of 2026-03-310,00 %$9M
- Institutional Investor · as of 2026-03-310,00 %$8M
- Investment Managers · as of 2026-03-310,00 %$10M
- Investment Managers · as of 2026-03-310,00 %$0M
- Funds · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$2M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Timothy P. HerbertPresident, Chief Executive Officer, Director
Insider activity
Net selling0 buys · 3 sellsnet -$176K16 insiders · last 365d
- Director · Common StockOther 5 631 · 2026-07-20
- Director · Common StockOther 346 · 2026-07-15
- Director · Common StockOther 344 · 2026-07-15
- Director · Common StockOther 383 · 2026-07-15
- Director · Common StockOther 581 · 2026-07-15
- See Remarks · Common StockSold 2 641 @ $43,28$114K · 2026-05-15
- See Remarks · Common StockSold 700 @ $43,01$30K · 2026-05-14
- Director · Common StockSold 696 @ $45,31$32K · 2026-05-08
- Director · Common StockOther 50 @ $56,70$3K · 2026-05-01
- Director · Common StockOther 3 562 · 2026-04-30
- Director · Common StockOther 3 562 · 2026-04-30
- Director · Common StockOther 3 562 · 2026-04-30
- Director · Common StockOther 3 562 · 2026-04-30
- Director · Common StockOther 3 562 · 2026-04-30
- Director · Common StockOther 3 562 · 2026-04-30
- Director · Common StockOther 3 562 · 2026-04-30
- Director · Common StockOther 3 562 · 2026-04-30
- Director · Common StockOther 307 @ $52,07$16K · 2026-04-15
- Director · Common StockOther 342 @ $52,07$18K · 2026-04-15
- Director · Common StockOther 518 @ $52,07$27K · 2026-04-15
- Director · Common StockOther 308 @ $52,07$16K · 2026-04-15
- Director, CEO and President · Common StockOther 9 005 · 2026-02-20
- Director, CEO and President · Common StockOther 4 010 @ $59,53$239K · 2026-02-20
- Director, CEO and President · Common StockOther 62 153 · 2026-02-20
- See Remarks · Common StockOther 2 400 · 2026-02-20
Short positioning
4.3Mshares short-7.5% vs prior
4.16days to cover
49.4%short of daily vol
4.0Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
INSP.KCanonical
NYSE · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Evidence & claims
From filings & derived data- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -9.6%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 13.3%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 12.2%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 6.3%Derived (calculated)
- Net margin (FY 2025-12-31): 15.9%Derived (calculated)
- Gross margin (FY 2025-12-31): 85.4%Derived (calculated)
- Return on equity (FY 2025-12-31): 18.6%Derived (calculated)
- Return on assets (FY 2025-12-31): 16.0%Derived (calculated)
- Current ratio (FY 2025-12-31): 6.08xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.16xDerived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -1.6%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -30.2%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 8.3%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 175.0%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 179.4%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): 14.6%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 171.8%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -10.2%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 41.2%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 13.6%Derived (calculated)
- Shareholders' equity (annual): USD 781.16MSEC XBRL filing
- Current liabilities (annual): USD 96.06MSEC XBRL filing
- Shares outstanding (annual): 28.58MSEC XBRL filing
- Current assets (annual): USD 583.65MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-08-03 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
2026-07-20INSIDERCARREL MICHAEL H transacted 5.6k sh — Director
2026-07-15INSIDERTansey Casey M transacted 346 sh — Director
2026-07-15INSIDERMelenikiotou Georgia transacted 344 sh — Director
2026-07-15INSIDERBroader Shelley G transacted 383 sh — Director
2026-07-15INSIDEREllis Gary Lee transacted 581 sh — Director
2026-05-15 00:00 UTCINSIDER4 insider transactions — 2026-05 · net sell $179k
2026-05-15 00:00 UTCINSIDER4 insider transactions — 2026-05 · net sell $179k
2026-05-15INSIDERRondoni John sold 2.6k sh — See Remarks ~$114k
2026-05-14INSIDERRondoni John sold 700 sh — See Remarks ~$30k
2026-05-08INSIDERmcCormick Shawn sold 696 sh — Director ~$32k
2026-05-01INSIDERMelenikiotou Georgia transacted 50 sh — Director ~$3k
2026-04-30 00:00 UTCINSIDER12 insider transactions — 2026-04
2026-04-30 00:00 UTCINSIDER12 insider transactions — 2026-04
2026-04-30INSIDERMead Dana G Jr. transacted 3.6k sh — Director
2026-04-30INSIDERTansey Casey M transacted 3.6k sh — Director
2026-04-30INSIDERCuret Myriam transacted 3.6k sh — Director
2026-04-30INSIDERBurks Cynthia transacted 3.6k sh — Director
2026-04-30INSIDERBroader Shelley G transacted 3.6k sh — Director
2026-04-30INSIDERmcCormick Shawn transacted 3.6k sh — Director
2026-04-30INSIDERMelenikiotou Georgia transacted 3.6k sh — Director
2026-04-30INSIDEREllis Gary Lee transacted 3.6k sh — Director
2026-04-15INSIDERMelenikiotou Georgia transacted 307 sh — Director ~$16k
2026-04-15INSIDERBroader Shelley G transacted 342 sh — Director ~$18k
2026-04-15INSIDEREllis Gary Lee transacted 518 sh — Director ~$27k
2026-04-15INSIDERTansey Casey M transacted 308 sh — Director ~$16k
2026-02-20 00:00 UTCINSIDER19 insider transactions — 2026-02 · net sell $535k
2026-02-20 00:00 UTCINSIDER19 insider transactions — 2026-02 · net sell $535k
2026-02-20INSIDERHerbert Timothy P. transacted 9.0k sh — Director, CEO and President
2026-02-20INSIDERHerbert Timothy P. transacted 4.0k sh — Director, CEO and President ~$239k
2026-02-20INSIDERHerbert Timothy P. transacted 62.2k sh — Director, CEO and President
2026-02-20INSIDERPhillips Bryan K transacted 2.4k sh — See Remarks
Showing the 40 most recent of 45 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage